Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES TAKEDA SUBSIDIARY LISTING<br />
Mar ket Re search: Michel Mauvetu; Re search &<br />
De vel op ment: Aszi Beukritly<br />
Sub sid iary of: Takeda, Neth er lands (100%)<br />
Phar ma ceu ti cal Sales: US$ 370-380 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 80-85%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 95-100%<br />
Dose Forms (% of Sales by Lead ing 5): n.a.<br />
Prin ci pal Prod ucts:<br />
ENANTONE (cytostatic hor mone)<br />
ACTOS (antidiabetic oral)<br />
KENZEN (an gio ten sin-II an tag o nist plain)<br />
OGAST (antiulcerant)<br />
COKENZEN (an gio ten sin-II an tag o nist com bi na -<br />
tion)<br />
Ther a peu tic Range:<br />
renin-an gio ten sin sys tem agents 27%<br />
ant ac ids/antiflatulents/antiulcerants 25%<br />
cytostatic hor mone ther apy 25%<br />
drugs used in di a be tes 22%<br />
antibacterials sys temic 1%<br />
Lead ing Dose Forms:<br />
tab lets 55%<br />
vi als 25%<br />
cap sules 15%<br />
coated tab lets 5%<br />
� GERMANY<br />
TAKEDA PHARMA<br />
Full Name: Takeda Pharma GmbH<br />
Street Ad dress: Viktoriaallee 3-5, D-52066<br />
Aachen<br />
Tel: +49 241 941-0<br />
Fax: +49 241 941-2769<br />
Email: info@takeda.de<br />
Home Page: www.takeda.de<br />
De scrip tion: De vel oper, ex porter, pro moter,<br />
sales/detailer. Prod uct ranges in clude: phar ma -<br />
ceu ti cal prod ucts (branded, pre scrip tion). Es tab -<br />
lished 1981.<br />
Con tacts (Pharm): Chair man: Noriaki Hada,<br />
Guenter Jo sephs; Com mer cial Op er a tions:<br />
Mathias Bosch; Mar ket Re search: Norbert<br />
Sarnes; Re search & De vel op ment: Reinhold<br />
Huebner<br />
Par ent of: Takeda Pharma, Aus tria (100%);<br />
Takeda Pharma, Swit zer land (100%).<br />
Sub sid iary of: Takeda, Neth er lands (100%)<br />
Phar ma ceu ti cal Sales: US$ 360-370 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 90-95%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 95-100%<br />
Dose Forms (% of Sales by Lead ing 5): n.a.<br />
Prin ci pal Prod ucts:<br />
TRENANTONE (cytostatic hor mone)<br />
BLOPRESS PLUS (an gio ten sin-II an tag o nist com -<br />
bi na tion)<br />
ACTOS (antidiabetic oral)<br />
BLOPRESS (an gio ten sin-II an tag o nist plain)<br />
COMPETACT (antidiabetic oral)<br />
Ther a peu tic Range:<br />
renin-an gio ten sin sys tem agents 36%<br />
cytostatic hor mone ther apy 34%<br />
drugs used in di a be tes 24%<br />
hor mones pi tu itary and hy po tha lamic 3%<br />
ant ac ids/antiflatulents/antiulcerants 2%<br />
Lead ing Dose Forms:<br />
tab lets 54%<br />
pre-filled sy ringes/pens 37%<br />
coated tab lets 7%<br />
cap sules 2%<br />
� INDONESIA<br />
TAKEDA<br />
Full Name: PT Takeda In do ne sia<br />
Street Ad dress: Plaza DM 15th Fl., Jl Jend.<br />
Sudirman Kav.25, Ja karta 12920<br />
Tel: +62 21 5267656<br />
Fax: +62 21 5267657<br />
De scrip tion: Man u fac turer, ex porter, pro moter.<br />
Prod uct ranges in clude: phar ma ceu ti cal prod ucts<br />
(branded, pre scrip tion, non-pre scrip tion). Es tab -<br />
lished 1971. 313 phar ma ceu ti cal employees in<br />
2007.<br />
Rep re sen ta tives/De tail ers (Pharm, Num -<br />
ber): 101-500 (2007)<br />
Con tacts (Pharm): Chair man: Hiromasa<br />
Okada; Com mer cial Op er a tions: Bahori Pohan<br />
(Sales); Man u fac ture: Alex M.T; Gen eral Con tact:<br />
Herlina Choirunnisa<br />
Sub sid iary of: Takeda, Ja pan (70%)<br />
Phar ma ceu ti cal Sales: US$ 24-26 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 60-65%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 70-75%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
95-100%<br />
Prin ci pal Prod ucts:<br />
VITACIMIN (vi ta min C plain/com bi na tion with<br />
min er als)<br />
BLOPRESS (an gio ten sin-II an tag o nist plain)<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 124
Change language